Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14099196 | 0.87 | MAPT (0.62) | MAPTALDH1A1SMN1; SMN2MAPK1CASP1 | |
| SCHEMBL634399 | 0.83 | ALDH1A1 (0.72) | TDP1MAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL6992814 | 0.83 | TDP1 (0.56) | TDP1MAPTALDH1A1SMN1; SMN2PABPC1 | |
| Hydrochloric Acid SCHEMBL10562751 | 0.82 | ALDH1A1 (0.69) | TDP1MAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3574871 | 0.82 | TDP1 (0.54) | TDP1MAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4111048 | 0.81 | KDM4E (0.50) | TDP1MAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL27985020 | 0.81 | TDP1 (0.48) | TDP1MAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL17616107 | 0.81 | KMT2A (0.47) | TDP1MAPTALDH1A1KDM4EKMT2A | |
| SCHEMBL4833903 | 0.79 | MAPT (0.54) | MAPTALDH1A1SMN1; SMN2MAPK1CASP1 | |
| SCHEMBL47270 | 0.79 | MAPT (0.54) | MAPTALDH1A1SMN1; SMN2MAPK1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2460789-B1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9079830-B2 | Method for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| US-20140235643-A1 | NOVEL QUINOXALINE INHIBITORS OF PI3K | GILEAD CALISTOGA LLC | 2014-08-21 | — | — | US | disclosed |
| US-20140235643-A1 | NOVEL QUINOXALINE INHIBITORS OF PI3K | GILEAD CALISTOGA LLC | 2014-08-21 | — | — | US | disclosed |
| US-20140235643-A1 | NOVEL QUINOXALINE INHIBITORS OF PI3K | GILEAD CALISTOGA LLC | 2014-08-21 | — | — | US | disclosed |
| EP-2763994-A2 | NOVEL QUINOXALINE INHIBITORS OF PI3K | Gilead Calistoga LLC (US) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013052699-A2 | NOVEL QUINOXALINE INHIBITORS OF PI3K | GILEAD CALISTOGA LLC (US) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013052699-A2 | NOVEL QUINOXALINE INHIBITORS OF PI3K | GILEAD CALISTOGA LLC (US) | 2013-04-11 | — | — | WO | disclosed |
| EP-2460789-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120123154-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123154-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | AKR7A2, AOC2, CBR1 | TDP1 4738/4885MAPT 2662/4885ALDH1A1 35/4885 |
| US-20140235643-A1 | NOVEL QUINOXALINE INHIBITORS OF PI3K | PIK3R5, PIK3CA, PIK3CD | TDP1 1610/4885MAPT 3207/4885ALDH1A1 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.